Arcellx, Inc. (NASDAQ:ACLX) Shares Acquired by Federated Hermes Inc.

Federated Hermes Inc. boosted its holdings in Arcellx, Inc. (NASDAQ:ACLX) by 141.4% during the fourth quarter, HoldingsChannel.com reports. The fund owned 156,094 shares of the company’s stock after acquiring an additional 91,430 shares during the period. Federated Hermes Inc.’s holdings in Arcellx were worth $11,971,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Vanguard Group Inc. raised its holdings in shares of Arcellx by 35.3% during the fourth quarter. Vanguard Group Inc. now owns 3,330,092 shares of the company’s stock valued at $255,385,000 after buying an additional 867,996 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Arcellx during the 4th quarter valued at $10,016,000. Geode Capital Management LLC lifted its stake in shares of Arcellx by 4.3% in the 3rd quarter. Geode Capital Management LLC now owns 974,967 shares of the company’s stock valued at $81,434,000 after purchasing an additional 39,781 shares during the last quarter. American Century Companies Inc. acquired a new stake in shares of Arcellx in the 4th quarter valued at $2,258,000. Finally, Bank of New York Mellon Corp lifted its position in Arcellx by 23.4% during the 4th quarter. Bank of New York Mellon Corp now owns 144,409 shares of the company’s stock worth $11,075,000 after acquiring an additional 27,350 shares during the last quarter. Institutional investors own 96.03% of the company’s stock.

Insider Transactions at Arcellx

In other news, insider Rami Elghandour sold 38,300 shares of the stock in a transaction on Wednesday, February 26th. The shares were sold at an average price of $62.02, for a total transaction of $2,375,366.00. Following the completion of the sale, the insider now owns 149,186 shares of the company’s stock, valued at $9,252,515.72. This represents a 20.43 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Kavita Patel sold 1,500 shares of the firm’s stock in a transaction on Tuesday, April 8th. The shares were sold at an average price of $57.50, for a total transaction of $86,250.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 55,955 shares of company stock worth $3,507,263. Corporate insiders own 6.24% of the company’s stock.

Arcellx Stock Performance

NASDAQ:ACLX opened at $59.16 on Thursday. The firm’s 50-day moving average is $65.77 and its 200-day moving average is $76.33. Arcellx, Inc. has a 52-week low of $47.88 and a 52-week high of $107.37. The company has a market cap of $3.25 billion, a price-to-earnings ratio of -83.32 and a beta of 0.33.

Arcellx (NASDAQ:ACLX) last posted its earnings results on Thursday, February 27th. The company reported ($0.87) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.24). The business had revenue of $15.27 million during the quarter, compared to the consensus estimate of $27.42 million. Arcellx had a negative net margin of 25.94% and a negative return on equity of 8.28%. Equities analysts predict that Arcellx, Inc. will post -1.58 EPS for the current year.

Arcellx Profile

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company’s lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).